Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

作者全名："Mao, Yimin; Ma, Shiwu; Liu, Chenghai; Liu, Xiaoyan; Su, Minghua; Li, Dongliang; Li, Yiling; Chen, Gongying; Chen, Jun; Chen, Jinjun; Zhao, Jingmin; Guo, Xiaoyan; Tang, Jieting; Zhuge, Yuzheng; Xie, Qing; Xie, Wen; Lai, Rongtao; Cai, Dachuan; Cai, Qingxian; Zhi, Yang; Li, Xiaoyun"

作者地址："[Mao, Yimin; Tang, Jieting; Zhi, Yang; Li, Xiaoyun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Res Ctr Fatty Liver Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab D, Shanghai 200001, Peoples R China; [Ma, Shiwu] 920th Hosp Chinese PLA Joint Logist Support Force, Dept Infect Dis, Kunming 650032, Yunnan, Peoples R China; [Liu, Chenghai] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Liver Dis, Shanghai 201203, Peoples R China; [Liu, Xiaoyan] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Pharm,Huangpu Branch, Shanghai 200011, Peoples R China; [Su, Minghua] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiol, Nanning 530021, Guangxi, Peoples R China; [Li, Dongliang] 900th Hosp Chinese PLA Joint Logist Support Force, Dept Hlth Med, Fuzhou 350025, Fujian, Peoples R China; [Li, Yiling] China Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Shenyang 110001, Liaoning, Peoples R China; [Chen, Gongying] Hangzhou Normal Univ, Dept Liver Dis, Affiliated Hosp, Hangzhou 310015, Zhejiang, Peoples R China; [Chen, Jun; Cai, Qingxian] Shenzhen Third Peoples Hosp, Dept Infect Dis, Shenzhen 518112, Guangdong, Peoples R China; [Chen, Jinjun] Southern Med Univ, Nanfang Hosp, Hepatol Ctr, Guangzhou 510515, Guangdong, Peoples R China; [Zhao, Jingmin] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Pathol & Hepatol, Beijing 100039, Peoples R China; [Guo, Xiaoyan] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gastroenterol, Xian 710004, Shaanxi, Peoples R China; [Zhuge, Yuzheng] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Gastroenterol, Nanjing 210008, Jiangsu, Peoples R China; [Xie, Qing; Lai, Rongtao] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Dis, Sch Med, Shanghai 200025, Peoples R China; [Xie, Wen] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Beijing 100088, Peoples R China; [Cai, Dachuan] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing 400010, Peoples R China"

通信作者："Mao, YM (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Res Ctr Fatty Liver Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab D, Shanghai 200001, Peoples R China."

来源：HEPATOLOGY INTERNATIONAL

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001170929600001

JCR分区：Q1

影响因子：6.6

年份：2024

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Editorial Material; Early Access

关键词：Drug; Herbal and dietary supplements; Liver injury; Guideline; Management; Diagnosis; Treatment; Prevention; Phenotypes; Prognosis

摘要："Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment."

基金机构："National Key R&D Program of China [2022YFC3502101]; Major Project of National Thirteenth Five Plan [2017ZX09304016]; National Natural Science Foundation of China [NSFC 81970513, NSFC 82270619]"

基金资助正文："This work was supported by the National Key R & D Program of China (Grant number 2022YFC3502101), the Major Project of National Thirteenth Five Plan (Grant number 2017ZX09304016), and the National Natural Science Foundation of China (Grant numbers NSFC 81970513 and NSFC 82270619), all to Yimin Mao"